<DOC>
	<DOC>NCT02134249</DOC>
	<brief_summary>The purpose of this study is to compare the effect of oral Diosmin to oral Cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in high-risk women underwent intracytoplasmic sperm injection (ICSI).</brief_summary>
	<brief_title>Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome</brief_title>
	<detailed_description>Two hundred women at risk of ovarian hyperstimulation syndrome during ICSI cycles will be randomly scheduled into two equal groups. In group A, (Diosmin group), 2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for 2 weeks ; while in group B (Cabergoline group), 1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for eight days.</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>infertile women undergoing intracytoplasmic sperm injection or polycystic ovarin syndrome (PCO) with one of the following: 1. Presence of more than 20 follicles by ultrasound 2. E2 more than 3000 pg/ml 3. Retrieval of more than 15 follicles</criteria>
	<gender>Female</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>infertility</keyword>
	<keyword>ICSI</keyword>
	<keyword>OHSS</keyword>
	<keyword>Diosmin</keyword>
	<keyword>Cabergoline</keyword>
</DOC>